Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Rishi Wadhera, MD, MPP, Mphil
Bridging ASCVD Care Between Academic and Rural Settings
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
prof. Hiddo Heerspink
Jennifer B. Green, MD
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Piotr Ponikowski, MD, PhD, FESC, FHFA
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
Akshay S. Desai, MD
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
FINE-HEART Pooled Analysis
Maria Pabon
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Jonathan Cunningham, MD
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
NYHA FC and Finerenone Response: Clinical Trial Insights
John Ostrominski
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Complexities in ATTR-CM Care: Key Considerations for Accurate Diagnosis
Gautam Nayak, MD
Overcoming Challenges in ATTR-CM Care: Best Practices for Accurate Diagnosis
Michelle Kittleson, MD, PhD
Patient Case Study: Obesity and VTE
Renato D. Lopes, MD, MHS, PhD
Alexander T. Cohen, MD, MBBS
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Cardiology Academy… but how about a more personalized experience?
Press cancel to remain on Global Cardiology Academy. Press the link below or the continue button to keep going.